Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection

Elena E Giorgi; Harikrishnan Balachandran; Mark Muldoon; Norman L Letvin; Barton F Haynes; Bette T Korber; Sampa Santra

doi:10.1016/j.vaccine.2014.04.040

Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection

Elena E Giorgi
, Harikrishnan Balachandran
, Mark Muldoon
, Norman L Letvin
, Barton F Haynes
, Bette T Korber
, Sampa Santra

Research output: Contribution to journal › Article › peer-review

Abstract

An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus. Evaluation of the breadth and magnitude of cellular immune responses to epitope variants is important for HIV-1 vaccine assessment. We compared HIV-1 Gag-specific T-lymphocyte responses in 20 HIV-1-infected individuals representing two different HIV-1 subtypes, B and C. By assessing T lymphocyte responses with peptides based on natural HIV-1 variants, we found evidence for limited cross-reactivity and significantly enhanced within-clade responses among clade B-infected subjects, and not among clade C-infected subjects.

Original language	English
Pages (from-to)	3995-4000
Number of pages	5
Journal	Vaccine
Volume	32
Issue number	31
DOIs	https://doi.org/10.1016/j.vaccine.2014.04.040
Publication status	Published - 2014

Keywords

HIV-1, HIV-1 vaccine, immunology, T-lymphocytes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2014.04.040

Cite this

@article{e13c6e1bac004721a6f47b67abe1bcbd,

title = "Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection",

abstract = "An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus. Evaluation of the breadth and magnitude of cellular immune responses to epitope variants is important for HIV-1 vaccine assessment. We compared HIV-1 Gag-specific T-lymphocyte responses in 20 HIV-1-infected individuals representing two different HIV-1 subtypes, B and C. By assessing T lymphocyte responses with peptides based on natural HIV-1 variants, we found evidence for limited cross-reactivity and significantly enhanced within-clade responses among clade B-infected subjects, and not among clade C-infected subjects.",

keywords = "HIV-1, HIV-1 vaccine, immunology, T-lymphocytes",

author = "Giorgi, \{Elena E\} and Harikrishnan Balachandran and Mark Muldoon and Letvin, \{Norman L\} and Haynes, \{Barton F\} and Korber, \{Bette T\} and Sampa Santra",

note = "This work was supported by grant from the NIH, NIAID U19- AI067854-07 (the Center for HIV/AIDS Vaccine Immunology).",

year = "2014",

doi = "10.1016/j.vaccine.2014.04.040",

language = "English",

volume = "32",

pages = "3995--4000",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "31",

}

TY - JOUR

T1 - Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection

AU - Giorgi, Elena E

AU - Balachandran, Harikrishnan

AU - Muldoon, Mark

AU - Letvin, Norman L

AU - Haynes, Barton F

AU - Korber, Bette T

AU - Santra, Sampa

N1 - This work was supported by grant from the NIH, NIAID U19- AI067854-07 (the Center for HIV/AIDS Vaccine Immunology).

PY - 2014

Y1 - 2014

N2 - An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus. Evaluation of the breadth and magnitude of cellular immune responses to epitope variants is important for HIV-1 vaccine assessment. We compared HIV-1 Gag-specific T-lymphocyte responses in 20 HIV-1-infected individuals representing two different HIV-1 subtypes, B and C. By assessing T lymphocyte responses with peptides based on natural HIV-1 variants, we found evidence for limited cross-reactivity and significantly enhanced within-clade responses among clade B-infected subjects, and not among clade C-infected subjects.

AB - An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus. Evaluation of the breadth and magnitude of cellular immune responses to epitope variants is important for HIV-1 vaccine assessment. We compared HIV-1 Gag-specific T-lymphocyte responses in 20 HIV-1-infected individuals representing two different HIV-1 subtypes, B and C. By assessing T lymphocyte responses with peptides based on natural HIV-1 variants, we found evidence for limited cross-reactivity and significantly enhanced within-clade responses among clade B-infected subjects, and not among clade C-infected subjects.

KW - HIV-1, HIV-1 vaccine, immunology, T-lymphocytes

U2 - 10.1016/j.vaccine.2014.04.040

DO - 10.1016/j.vaccine.2014.04.040

M3 - Article

SN - 0264-410X

VL - 32

SP - 3995

EP - 4000

JO - Vaccine

JF - Vaccine

IS - 31

ER -

Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this